实现生物标志物的有意义临床应用。
Making Meaningful Clinical Use of Biomarkers.
作者信息
Selleck Matthew J, Senthil Maheswari, Wall Nathan R
机构信息
Division of Surgical Oncology, Department of Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA.
Division of Biochemistry, Department of Basic Sciences and Center for Health Disparities & Molecular Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA.
出版信息
Biomark Insights. 2017 Jun 19;12:1177271917715236. doi: 10.1177/1177271917715236. eCollection 2017.
Abstract
This review discusses the current state of biomarker discovery for the purposes of diagnostics and therapeutic monitoring. We underscore relevant challenges that have defined the gap between biomarker discovery and meaningful clinical use. We highlight recent advancements in and propose a way to think about future biomarker development.
摘要
本综述讨论了用于诊断和治疗监测的生物标志物发现的现状。我们强调了那些界定了生物标志物发现与有意义的临床应用之间差距的相关挑战。我们突出了近期的进展，并提出了一种思考未来生物标志物发展的方法。
相似文献
1
Making Meaningful Clinical Use of Biomarkers.实现生物标志物的有意义临床应用。
Biomark Insights. 2017 Jun 19;12:1177271917715236. doi: 10.1177/1177271917715236. eCollection 2017.
2
Emerging Concepts and Methodologies in Cancer Biomarker Discovery.癌症生物标志物发现中的新兴概念与方法
Crit Rev Oncog. 2017;22(5-6):371-388. doi: 10.1615/CritRevOncog.2017020626.
3
Proteomic-based biomarker discovery for development of next generation diagnostics.基于蛋白质组学的生物标志物发现，用于下一代诊断技术的开发。
Appl Microbiol Biotechnol. 2017 Jan;101(2):475-491. doi: 10.1007/s00253-016-8029-z. Epub 2016 Dec 24.
4
The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.药物性肝毒性检测的蛋白质组学安全生物标志物的发现和研制。
Toxicol Appl Pharmacol. 2010 May 15;245(1):134-42. doi: 10.1016/j.taap.2010.02.011. Epub 2010 Feb 26.
5
Urine as a source for clinical proteome analysis: from discovery to clinical application.尿液作为临床蛋白质组分析的来源：从发现到临床应用。
Biochim Biophys Acta. 2014 May;1844(5):884-98. doi: 10.1016/j.bbapap.2013.06.016. Epub 2013 Jul 2.
6
Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.预测性分子生物标志物指导肾癌的临床决策：当前进展与未来挑战。
Expert Rev Mol Diagn. 2015 May;15(5):631-46. doi: 10.1586/14737159.2015.1032261. Epub 2015 Apr 3.
7
Biomarker rediscovery in diagnostics.诊断学中的生物标志物重新发现
Expert Opin Med Diagn. 2008 Dec;2(12):1391-400. doi: 10.1517/17530050802566488. Epub 2008 Nov 13.
8
Highlights of the Third Annual Biomarker World Congress: biomarkers for molecular diagnostics.第三届年度生物标志物世界大会亮点：分子诊断生物标志物
Expert Opin Med Diagn. 2007 Sep;1(1):147-50. doi: 10.1517/17530059.1.1.147.
9
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.液体活检在胰腺癌诊断、预后和治疗监测中的新兴作用。
Pharmacogenomics. 2019 Jan;20(1):49-68. doi: 10.2217/pgs-2018-0149. Epub 2018 Dec 6.
10
Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics.整体乳腺癌管理中的潜在生物标志物组合：多级诊断的进展
Per Med. 2016 Sep;13(5):469-484. doi: 10.2217/pme-2016-0020. Epub 2016 Jul 27.
引用本文的文献
1
Circulating CHI3L1 autoantibodies serve as a diagnostic biomarker in patients with obstructive sleep apnea.循环中的几丁质酶3样蛋白1自身抗体可作为阻塞性睡眠呼吸暂停患者的诊断生物标志物。
Sci Rep. 2025 Jul 25;15(1):27087. doi: 10.1038/s41598-025-11537-2.
2
Assessing Random Forest self-reproducibility for optimal short biomarker signature discovery.评估随机森林的自再现性以发现最佳的短生物标志物特征。
Brief Bioinform. 2025 Jul 2;26(4). doi: 10.1093/bib/bbaf318.
3
Electrochemical Microneedles for Real-Time Monitoring in Interstitial Fluid: Emerging Technologies and Future Directions.用于间质液实时监测的电化学微针：新兴技术与未来方向
Biosensors (Basel). 2025 Jun 12;15(6):380. doi: 10.3390/bios15060380.
4
Serum creatinine to cystatin C ratio as monitoring biomarker in Chinese adult spinal muscular atrophy: a prospective cohort study.血清肌酐与胱抑素C比值作为中国成人脊髓性肌萎缩症监测生物标志物的前瞻性队列研究。
Orphanet J Rare Dis. 2025 May 2;20(1):209. doi: 10.1186/s13023-025-03730-3.
5
Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.解读微小RNA在肝细胞癌中的多方面作用：整合文献综述与生物信息学分析以获取治疗见解
Heliyon. 2024 Oct 18;10(20):e39489. doi: 10.1016/j.heliyon.2024.e39489. eCollection 2024 Oct 30.
6
"My Biomarkers Are Fine, Thank You": On the Biomarkerization of Modern Medicine.“我的生物标志物没问题，谢谢”：论现代医学的生物标志物化
J Gen Intern Med. 2025 Feb;40(2):453-457. doi: 10.1007/s11606-024-09019-8. Epub 2024 Sep 25.
7
An original study assessing biomarker success rate in breast cancer recurrence biomarker research.评估乳腺癌复发生物标志物研究中生物标志物成功率的原始研究。
BMC Med. 2024 Jul 29;22(1):307. doi: 10.1186/s12916-024-03460-6.
8
Unveiling Colorectal Cancer Biomarkers: Harnessing Biosensor Technology for Volatile Organic Compound Detection.揭示结直肠癌生物标志物：利用生物传感器技术检测挥发性有机化合物。
Sensors (Basel). 2024 Jul 20;24(14):4712. doi: 10.3390/s24144712.
9
Design, cohort profile and comparison of the KTD-Innov study: a prospective multidimensional biomarker validation study in kidney allograft rejection.设计、队列特征及 KTD-Innov 研究的比较：肾移植排斥反应前瞻性多维生物标志物验证研究。
Eur J Epidemiol. 2024 May;39(5):549-564. doi: 10.1007/s10654-024-01112-w. Epub 2024 Apr 16.
10
Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers.在分析与肌肉减少症相关的生物标志物时应考虑糖尿病。
J Clin Med. 2024 Feb 15;13(4):1107. doi: 10.3390/jcm13041107.
本文引用的文献
1
Clinically Meaningful Use of Blood Tumor Markers in Oncology.血液肿瘤标志物在肿瘤学中的临床意义性应用。
Biomed Res Int. 2016;2016:9795269. doi: 10.1155/2016/9795269. Epub 2016 Nov 30.
2
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).第三届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 3）
Breast. 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5.
3
Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer.反应生物标志物：重新构想为癌症量身定制药物治疗的方法。
BMC Cancer. 2016 Nov 5;16(1):850. doi: 10.1186/s12885-016-2886-9.
4
Predicting the Future - Big Data, Machine Learning, and Clinical Medicine.预测未来——大数据、机器学习与临床医学。
N Engl J Med. 2016 Sep 29;375(13):1216-9. doi: 10.1056/NEJMp1606181.
5
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice.临床研究中的统计学争议：预后基因特征目前在临床实践中并无用处。
Ann Oncol. 2016 Dec;27(12):2160-2167. doi: 10.1093/annonc/mdw307. Epub 2016 Sep 15.
6
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer.蛋白质组学在前列腺癌生物标志物开发中的作用，以改善患者诊断和临床决策。
Diagnostics (Basel). 2016 Jul 18;6(3):27. doi: 10.3390/diagnostics6030027.
7
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.ESMO 共识指南：转移性结直肠癌患者的管理。
Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.
8
Predicting Clinical Outcomes Using Molecular Biomarkers.使用分子生物标志物预测临床结果
Biomark Cancer. 2016 Jun 6;8:89-99. doi: 10.4137/BIC.S33380. eCollection 2016.
9
New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.癌症生物标志物的新概念：液体活检中的循环微小RNA
Int J Mol Sci. 2016 Apr 27;17(5):627. doi: 10.3390/ijms17050627.
10
Systemic Chemotherapy in Advanced Pancreatic Cancer.晚期胰腺癌的全身化疗
Gut Liver. 2016 May 23;10(3):340-7. doi: 10.5009/gnl15465.
Zotero 插件